Print Page Print Page  |  RSS Feeds RSS Feeds  |  E-mail Alerts E-mail Alerts  |  IR Contacts IR Contacts  |  Financial Tear Sheet Financial Tear Sheet

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/02/18Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have performed the 500th PHP Therapy® treatment using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). CHEMOSAT was launched in select European markets in 2012, and physicians there have used it to treat a wide variety of cancers of the liver.   Jennifer K. Simpson, ... 
Printer Friendly Version
02/01/18Delcath Announces Satisfaction of 2016 Convertible Note
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has satisfied all of its obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016.  On December 28, 2017, Delcath entered into exchange agreements with  two institutional investors pursuant to which those investors were issued, in ex... 
Printer Friendly Version
01/10/18Delcath Announces Special Protocol Agreement Modification With FDA
NEW YORK, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has concluded a modification agreement with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with hepatic dominant ocular melanoma (The FOCUS Trial).... 
Printer Friendly Version
01/09/18Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi-center retrospective analysis of Delcath’s PHP® Therapy have been published in the peer-reviewed Journal of Surgical Oncology. The study, Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease, was conducted by r... 
Printer Friendly Version